Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression

Molecular Biology Reports

Volumn 38, Issue 6, 2011, Pages 3671-3677

  Chen, Rong Xin ^a,b   Xia, Yun Hong ^a,b   Xue, Tong Chun ^a,b   Ye, Sheng Long ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Hepatocellular carcinoma; Invasion; Osteopontin

Indexed keywords

CANCER ANTIBODY; CD44V6 ANTIGEN; GELATINASE A; OSTEOPONTIN; UROKINASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL INTERACTION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA MICROARRAY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UNINDEXED SEQUENCE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CLONE CELLS; COLLAGEN; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; OSTEOPONTIN; PLASMIDS; PROTEOGLYCANS; RNA, MESSENGER; TRANSFECTION; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80052446947     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0481-8     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. doi:10.3322/canjclin.55.2.74. (Pubitemid 40372904)
2. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917. doi:10.1016/S0140-6736(03)149 64-1. (Pubitemid 37518510)
3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD (2004) A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187-196. doi:10.1007/s00432-003-0511-1. (Pubitemid 38553626)
4. Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103-118. doi:10.1007/s10555-007-9104-9.
5. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87. doi:10.1016/j.tcb.2005.12.005. (Pubitemid 43247403)
6. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416-423. doi: 10.1038/nm843. (Pubitemid 36460075)
7. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184-190. doi:10.1158/1078-0432.CCR-1405-2. (Pubitemid 38114178)
8. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463-474. doi:10.1016/j.cytogfr.2006.09. 010. (Pubitemid 44793123)
9. Kapoor P, Suva LJ, Welch DR, Donahue HJ (2008) Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 103:30-41. doi:10.1002/jcb.21382.
10. Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P (2006) Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66:883-888. doi:10.1158/0008-5472. CAN-05-2816. (Pubitemid 43165954)
11. Lin HM, Chatterjee A, Lin YH, Anjomshoaa A, Fukuzawa R, McCall JL, Reeve AE (2007) Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep 17:1541-1549.
12. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119-127. doi:10.1002/cncr.11487. (Pubitemid 36741134)
13. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361-6371. doi:10.1038/sj.onc.1210463. (Pubitemid 47494216)
14. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX (2008) Lentiviralmediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48:1834-1842. doi:10.1002/hep.22531.
15. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14:7470-7480. doi:10.1158/1078-0432.CCR-08-0870.
16. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC (2005) Osteopontin: it's role in regulation of cell motility and nuclear factor κB-mediated urokinase type plasminogen activator expression. IUBMB Life 57:441-447. doi:10.1080/15216540500159424. (Pubitemid 41073126)
17. El-Tanani MK (2008) Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 13:4276-4284. doi: 10.2741/3004. (Pubitemid 351599683)
18. Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP, Boudjema K, Clement B (2001) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34:82-88. doi: 10.1053/jhep.2001.25758. (Pubitemid 32591486)
19. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO (2004) Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 10:4140-4149. doi: 10.1158/1078-0432.CCR-03-0574. (Pubitemid 38812494)